Sleep in Patients With Cystic Fibrosis

NCT ID: NCT00804661

Last Updated: 2010-06-03

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 76 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2007-07-31
• Study Completion Date: 2009-06-30

Brief Summary

The aim of the study is to identify the parameters that are associated with nocturnal hypoventilation in children and adults with cystic fibrosis. Included patients will undergo a nocturnal evaluation of their gas exchange and sleep quality by actigraphy during their annual check up. The aim is thus to identify which parameters (such as lung function parameters) are associated with nocturnal hypercapnia or hypoxemia and/or poor sleep quality

Detailed Description

Background In patients with cystic fibrosis (CF), respiratory disease is characterised by a progressive and ineluctable decline in lung function. Sleep-disordered breathing may occur at an early stage of lung disease and may impair quality of life. Oxygen therapy or noninvasive positive pressure ventilation may improve nocturnal hypoxemia and hypercapnia.Risk factors for nocturnal hypercapnia or hypoxemia are not well identified in patients with CF.

Type of study : prospective, transversal, open

Methods :

During the annual check up, a sleep study will be performed with a nocturnal recording of a least 6 hours of pulse oximetry (SaO2) and transcutaneous carbon dioxide (PtcCO2) by the SENTEC device and wrist movements by means of actigraphy. The results of the sleep study will be correlated to·

• clinical scores which evaluate sleep quality (such as the PITTSBURG Sleep Quality Score).·
• respiratory function parameters : lung volumes, forced expiratory of the respiratory muscles: maximal inspiratory and expiratory pressures and the sniff nasal inspiratory pressure.·
• nutritional state with the body mass index z-score·
• the presence of arterial pulmonary hypertension on an echocardiography·
• infectious status (colonisation by Staphylococcus aureus or Pseudomonas aeruginosa) and the CFTR genotype.

Expected results This study should be able to document abnormal nocturnal gas exchange and sleep-disordered breathing in patients with CF in a stable state. The identification of parameters associated with nocturnal hypoventilation and/or poor sleep quality will help to screen those patients who will need a sleep study and treatment such as oxygen therapy or noninvasive positive pressure ventilation.

Conditions

Cystic Fibrosis

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

1

Children and adults with cystic fibrosis

SENTEC device

Intervention Type: DEVICE

Nocturnal recording SAO2 and PtcCO2 and wrist movements by means of actigraphy

Interventions

SENTEC device

Nocturnal recording SAO2 and PtcCO2 and wrist movements by means of actigraphy

Intervention Type: DEVICE

Other Intervention Names

Nocturnal SAO2/PtcCO2 and wrist movements

Eligibility Criteria

Inclusion Criteria

• children > 8 years and adults with CF
• in a stable state (no acute respiratory exacerbation since one month or patient finishing an antibiotic course)
• able to perform reproducible forced expiratory flows
• having a forced expiratory volume in one second ≤ 60% predicted value
• who accepts to perform a sleep study in the hospital during one night
• written agreement to participate to the study

Exclusion Criteria

• acute respiratory exacerbation in the previous month or patient who has not finished an antibiotic course
• Inability or impossibility to perform reproducible forced expiratory flows (pneumothorax during the previous year and/or without surgery)
• having a forced expiratory volume in one second > 60% predicted value
• refusal or impossibility to perform a sleep study in the hospital during one night
• patients receiving long term oxygen therapy or noninvasive positive pressure ventilation
• no social security
• impossibility of a medical examination

• Minimum Eligible Age: 8 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Department Clinical Research of Developpement

Principal Investigators

Brigitte Fauroux, MD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Locations

AP-HP, Armand Trousseau hospital

Paris, , France

Countries

France

Other Identifiers

P070202

Identifier Type: -

Identifier Source: org_study_id